Case 2: Coinfection. Patient Case
|
|
- Mervin Myron Paul
- 6 years ago
- Views:
Transcription
1 Case 2: Coinfection Jennifer J. Kiser, PharmD Assistant Professor University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences Aurora, Colorado FORMATTED: Learning Objectives After attending this presentation, learners will be able to: Identify HCV treatment options for persons with HIV coinfection Describe drug interaction potential with current and future DAAs with ARV agents Determine the management of interactions Slide 2 of XX Patient Case Slide 3 of yo Hispanic male HIV diagnosed 20 years ago HCV diagnosed 2 years ago Insomnia ½ ppd smoker x 20 years Occasional EtOH History of substance abuse in remission x 4 years History of depression while using drugs 1
2 HIV History Slide 4 of 54 Most recent VL and CD4 (1/14) HIV RNA 59 copies/ml (30 copies/ml in 10/13) CD4 768 cells/µl (24%) CD4 nadir = 6 cells/µl (has had PCPx2, thrush) ARV History Reports taking ARV since diagnosis except for ~1 year during period of active substance abuse Currently taking TDF/FTC 300mg/200mg QD and ATV/r 300/100 QD Had a viral load of 2200 copies/ml in July, genotype performed with no evidence of resistance HCV History Slide 5 of 54 Treatment naive Genotype 1b HCV RNA (7/13) 4,650,000 IU/mL (6.67 log 10 IU/mL) Liver biopsy (12/13): Chronic hepatitis with mild activity and multifocal delicate bridging fibrosis, consistent with history of hepatitis C (Grade 2, Stage 3) Minimal macrovesicular steatosis Abdominal CT ( AFP 28.4 ng/ml, ref range 0 9 ng/ml), 1/14: No arterially enhancing hepatic lesion or other findings of concern for hepatocellular carcinoma Although the liver is unremarkable in size and morphology, recannulization of the umbilical vein, mild splenomegaly and slight prominence of the retroperitoneal nodal tissues are suggestive of portal hypertension Clinical Labs Slide 6 of 54 ALT 52 U/L (0 47) AST 41 U/L (0 47) Alk Phos 84 U/L (39 117) Tbili 3.3 mg/dl (0 1.3)* Albumin 4.0 g/dl (3.4 5) INR 1.0 ( ) SCr 1.08 mg/dl ( ) Wt 87 kg, Ht 5 7 CrCl ~87 ml/min WBC /L (4 11.1) ANC /L ( ) RBC /L ( ) Hgb 16.8 g/dl ( ) Hct 48.2% (39.2 to 50.2) Platelet /L ( )* 2
3 Current Medications Slide 7 of 54 TDF/FTC 300/200mg po QD ATV/r 300/100mg po QD Trazodone 50mg po QHS prn Zolpidem 5mg po QHS Audience Response #1: Given this patient s current and past medical history, I would treat with: Slide 8 of Peginterferon plus ribavirin plus sofosbuvir x 12 weeks 2. Sofosbuvir plus ribavirin x 24 weeks 3. Peginterferon plus ribavirin plus simeprevir x 12 weeks, followed by peginterferon plus ribavirin 4. Sofosbuvir plus simeprevir with or without ribavirin x 12 weeks 5. I would not treat this patient s HCV now Slide 9 of 54 If we treat now what s the data? 3
4 Slide 10 of 54 SOF+RBV in HIV/HCV (PHOTON) Study Design Wk 0 Wk 12 Wk 24 Wk 36 Wk 48 GT 1 TN SOF + RBV, n=114 GT 2/3 TN GT 2/3 TE SOF + RBV, n=68 SOF + RBV, n=41 SVR 12 SVR 24 Broad inclusion criteria Cirrhosis permitted with no platelet cutoff Hemoglobin: 12 mg/dl (males); 11 mg/dl (females) Wide range of ART regimens allowed Undetectable HIV RNA for >8 weeks on stable ART regimen Baseline CD4 count ART treated: CD4 T-cell count >200 cells/mm 3 and HIV RNA < 50 c/ml ART untreated: CD4 T-cell count >500 cells/mm 3 Slide 11 of 54 PHOTON Baseline Demographics Treatment Naive GT 1 n=114 GT 2/3 n=68 Treatment Experienced GT 2/3 n=41 Mean age, y (range) 48 (25-70) 49 (24-71) 54 (34-68) Male, n (%) 93 (82%) 55 (81%) 37 (90%) Black, n (%) 37 (32%) 8 (12%) 7 (17%) Hispanic, n (%) 25 (22%) 19 (28%) 10 (24%) Mean BMI, kg/m 2 (range) 27 (18-46) 27 (20-43) 27 (19-40) Genotype 1a, n (%) 90 (79) NA NA Genotype 2, n (%) NA 26 (38) 24 (59) Genotype 3, n (%) NA 42 (62) 17 (41) IL28B CC, n (%) 30 (27) 25 (37) 20 (49) Mean HCV RNA, log 10 IU/mL (range) 6.6 ( ) 6.3 ( ) 6.5 ( ) Cirrhosis, n (%) 5 (4) 7 (10) 10 (24) On ART, n (%) 112 (98) 61 (90) 39 (95) CD4 T cell count (cells/μl), mean (SD) 636 (251) 585 (246) 658 (333) SOF+RBV x 24 wks in HIV/HCV Virologic Response: Genotype 1 Slide 12 of 54 Patients with HCV RNA <LLOQ (%) 110/ /103 87/114 22/23 virologic failures were by relapse, 1 with breakthrough was presumed nonadherent 86/114 Week 4 EOT SVR12 SVR24 4
5 Slide 13 of 54 SMV x 12 wks + PegIFN/RBV x wks: HIV/HCV Geno 1 (Study C212) 88% naives eligible for RGT (87% SVR12) G1b SVR 89% vs G1a(d) 71% Il28CC favorable predictor Dieterich, CROI, 2014 SOF + PegIFN/RBV x 12 wks (NEUTRINO) HCV-monoinfected Ph III, Rx-naive, GT1,4,5,6 Slide 14 of 54 n=327 n=292 n=28 n=7 All GT1 GT4 GT5,6 SVR 80% in cirrhotics SVR 71% if multiple bad prognostic factors (G1, F3/F4, IL28 non CC, HCV RNA>800k) Lawitz et al. NEJM 2013 Slide 15 of 54 SOF + PegIFN/RBV x 12 wks in Coinfected (n=23) 2/23 without SVR 1 relapse 1 early d/c at wk 6 Included only Rx naïve, no cirrhosis, cd4>200 Included geno 1a,>1b>3> 2 Rodriguez-Torres, et al. ID Week
6 Slide 16 of 54 HCV versus HIV/HCV GT1 in Clinical Trials (Not head to head comparisons) SVR Rate 40/64 28/38 13/15 16/28 42/53 206/260 15/23 9/17 419/521 7/10 260/292 17/1 9 17/2 87/ Poordad F et al, NEJM 2011; 364: vs. Sulkowski et al. Lancet Infect Dis 2013; 13(7): Jacobson I et al, NEJM 2011; 364: vs. Sulkowski et al. Ann Intern Med 2013; 159(2): Antiviral Drugs Advisory Committee Meeting, FDA review, 10/24/13 C208, C216, C206, C212, HPC3007, Dieterich, 14 th European AIDS Conference, 2013 Lawitz et al. NEJM 2013 versus Torres Rodriguez et al., IDSA 2013 Osinusi et al., JAMA 2013;310(8): versus Sulkowski et al. AASLD 2013 (PHOTON) Slide 17 of 54 COSMOS: Nucleotide + Protease inhibitor Cohort 1 GT1 null F0 F2 78% 1a 50% Q80K 6% CC N=24 N=15 N=27 N=14 SOF/SMV/r SOF/SMV SOF/SMV/r SOF/SMV Weeks N=30 N=16 N=27 N=14 Cohort 2 GT1 naïve/null (54% null) F3 F4 (47% F4) 78% 1a 40% Q80K 21% CC SOF 400mg QD + SMV 150mg QD +/ RBV (weight based) Sulkowski M. EASL Lawitz E. EASL Response (%) Slide 18 of 54 COSMOS: Nucleotide + Protease inhibitor Cohort 1 Cohort 2 100% % % 60 40% 40 20% 20 0% 24 R 24 No R 12 R 12 No R SVR12 Lost Relapse 3 relapses: all 1a with Q80K 0 24 R 24 No R 12 R 12 No R SVR12 Lost Relapse 3 relapses: all 1a with F3 or F4 Sulkowski M. EASL Lawitz E. EASL
7 AASLD/IDSA/IAS USA Guidance Recommendations for GT1 Treatment naïve and prior relapser PEG/RBV + SOF x 12 weeks in those who can tolerate interferon SOF/RBV x 24 weeks or SOF/SIM x 12 weeks for interferon ineligible/unwilling Treatment experienced: SOF/SIM x 12 weeks Slide 19 of 54 Slide 20 of 54 IFN ineligible is defined as one or more: Intolerance to IFN Autoimmune hepatitis and other autoimmune disorders Hypersensitivity to PEG or any of its components Decompensated hepatic disease History of depression, or clinical features consistent with depression Baseline Cytopenias neutrophil count below 1500/μL platelet count below 90,000/μL hemoglobin below 10 g/dl A history of preexisting cardiac disease Simeprevir Clinical Pharmacology Slide 21 of 54 HCV Protease Inhibitor Food exposures ~60% 99.9% protein bound primarily to albumin Primarily metabolized by CYP3A Eliminated via biliary excretion, less than 1% renal elimination 7
8 Slide 22 of 29 Simeprevir in Hepatic Impairment Compared with healthy matched controls, simeprevir AUC in moderate and severe hepatic impairment is 2.4 and 5-fold higher, respectively BUT only 1.3 and 2.8-fold higher than concentrations observed in Child-Pugh A cirrhotics in OPERA-1 study. Ouwerkerk-Mahadaven S. et al. EASL 2013 Simeprevir Interaction Potential Slide 23 of 54 Victim CYP3A substrate P gp and OATP1B1/3 substrate Perpetrator Mild inhibitor of CYP1A2 and intestinal 3A4 Inhibitor of OATP1B1/3, P gp, and MRP2 Slide 24 of 54 Transporter Mediated Interactions Like enzymes, transporter expression can be induced and transporter function can be inhibited. OATP1B1 Hepatocyte P gp, MRP2, BCRP, BSEP 8
9 Sofosbuvir Clinical Pharmacology Slide 25 of 54 NS5B Polymerase Inhibitor Uridine nucleotide analog 61 65% protein bound Renally eliminated In plasma, SOF accounts for only ~4% of the drug related material, majority (>90%) is GS Plasma Sofosbuvir Sofosbuvir Hepatocyte GS Slide 26 of 54 hce1,cata GS GS ACTIVE FORM GS HINT1 GS MP TP DP MP GS GS Made from: Mathias A, et al. 63 rd AASLD, Nov 9 13, 2012, abstract 1869, Sofia MJ, et al. J. Med. Chem. 2010, 53, , Murakami E, et al. J Biol Chem 2010;285: Renal Impairment Slide 27 of 29 Cornpropst M, et al. EASL
10 Sofosbuvir Interaction Potential Slide 28 of 54 Victim P gp and BCRP substrate Perpetrator Very low potential for altering PK of other agents In vitro not an inhibitor or inducer of CYP450, UGT1A1, P gp, BCRP, OATP1B1, OCT1, BSEP Slide 29 of 54 No significant PK interactions between SOF and common ART Kirby AASLD 2012 SOF and 007 Pharmacokinetics with ARV Slide 30 of 54 Kirby AASLD
11 ARV Pharmacokinetics Slide 31 of 54 Kirby AASLD 2012 Audience Response #2: If we include simeprevir in our HCV regimen what ARV changes are needed? Slide 32 of None, there are no clinically significant interactions with simeprevir and his ARV regimen 2. The patient could be switched to TDF/FTC plus efavirenz 3. The patient could be switched to TDF/FTC plus raltegravir 4. I would do something else Slide 33 of 54 Darunavir/Ritonavir Increases Simeprevir Exposures 2.6 fold even after reducing the simeprevir dose by 2/3 Ouwerkerk Mahadaven S, et al. IDWeek
12 Efavirenz Reduces Simeprevir Exposures by 71% Slide 34 of 54 Ouwerkerk Mahadaven S, et al. IDWeek 2012 Slide 35 of 54 Raltegravir Does Not Affect Simeprevir (and Vice Versa) Ouwerkerk Mahadaven S, et al. IDWeek 2012 ARV Interaction Score Card Slide 36 of 54 Simeprevir Sofosbuvir ATV/r No data No data DRV/r SIM ; DRV SOF ; DRV LPV/r No data No data TPV/r No data No data EFV SIM ; EFV SOF ; EFV RPV SIM ; RPV SOF ; RPV ETV No data No data RAL SIM ; RAL RAL ELV/cobi No data No data DLG No data No data MVC No data No data 12
13 Tipranavir is a P-gp Inducer SQV/r 1000/200 APV/r 600/200 LPV/r 400/100 ATV/r 300/100 ETV 800/ AUC Cmin Leith J, et al. 5 th Clin Pharm Workshop, Rome, Italy. April 1-3, Abs 34 Schoeller M, et al. 13th CROI 2006; abstract 583, Sabo J, et al. 7th PK Workshop, April 2006 abstract 41. Psychotropics Slide 38 of 54 Trazodone Metabolized by CYP3A Monitor for nausea, dizziness, hypotension, and syncope Zolpidem Multiple routes of metabolism hydroxylation and oxidation by CYP3A4, CYP2C9, CYP1A2, CYP2D6 and CYP2C19 No pre emptive dose reductions for psychotropics, monitor for psychotropic toxicities Audience Response #3: Which of the following agents could conceivably interact with sofosbuvir? 1. Rifampin 2. Carbamazepine 3. St John s Wort 4. All of the above Slide 39 of 54 13
14 Slide 40 of 54 Other Therapeutic Classes to Consider Low Potential for Interactions with Either Simeprevir or Sofosbuvir Potential or Documented Interactions with Simeprevir Potential Interactions with Sofosbuvir Methadone Rifamycins Rifamycins Opioids Antiepileptics Antiepileptics Oral contraceptives Herbals Herbals Immunosuppressants* HMG Co A reductase inhibitors Warfarin Calcium Channel Blockers Inhaled/intranasal corticosteroids Gastric Acid Modifiers Phosphodiesterase Inhibitors for ED * Still perform therapeutic drug monitoring for the immunosuppressants Slide 41 of 54 Resources for Drug Interactions University of Liverpool druginteractions.org Toronto General Hospital University of Buffalo ACTG Pharmacology Support Laboratory Specific to antiretroviral interactions DHHS Guidelines Drug Interaction Tables Slide 42 of 54 What if we wait a few months? 14
15 Slide 43 of 54 Risk of Liver Decompensation in HIV/HCV w/ Advanced Fibrosis The incidence of decompensation was 1.4 (95% CI, 0.7 2) per 100 personyears for subjects with fibrosis stage 3 vs 3.1 (95% CI, ) per 100 personyears for patients with cirrhosis. The incidence of decompensation was 0.9 (95% CI,.4 2) per 100 personyears for subjects with LSM 9.5 kpa and <14.6 kpa and 4 (95% CI, 3 5.2) per 100 person years for patients with LSM 14.6 kpa. Macias et al, CID, 2013 Slide 44 of 54 Preliminary Results: SOF/LDV in Persons with HCV/HIV Coinfection ERADICATE. Osinusi A, EASL 2014 Slide 45 of 54 Preliminary Results: SOF/LDV in Persons with HCV/HIV Coinfection ERADICATE. Osinusi A, EASL
16 Slide 46 of 54 Preliminary Results: SOF/LDV in Persons with HCV/HIV Coinfection ERADICATE. Osinusi A, EASL 2014 Slide 47 of 54 Preliminary Results: SOF/LDV in Persons with HCV/HIV Coinfection Preliminary results compare favorably with ION studies in HCV monoinfection ERADICATE. Osinusi A, EASL 2014 AbbVie Phase 3 Results in Monoinfected Patients Slide 48 of 54 Naives 1 Experienced 2 Overall 96% SVR with 12 weeks of ABT450/r + ombitasvir + dasabuvir + RBV SAPPHIRES I and II. 1 Feld JJ, EASL 2014, 2 Zeuzem S, EASL
17 Some Ongoing Coinfection Trials Slide 49 of 54 NCT NCT Drugs ABT450/r + ombitasvir (ABT267/NS5A) + dasabuvir (ABT333/NNI) (TURQUOISE 1) Daclatasvir (DCV)+ Sofosbuvir (SOF) (ALLY 2) Population N=300 genotype 1 12 vs. 24 weeks Treatment naïve and experienced Decompensation exclusion N=200 genotype 1, 2, 3, 4, 5, or 6 8 vs. 12 weeks for treatment naïve 12 weeks for treatment experienced Decompensation exclusion Pharmacology of Investigational DAA CYP3A Interaction Potential substrate? Faldaprevir (PI) Substrate and ᴓ of CYP3A4 and OATP1B1, substrate of P gp and MRP2, ᴓ UGT1A1 ARV DDI data DRV/r FDV* EFV FDV* Daclatasvir (NS5A) Substrate and ᴓ of P gp ATV/r DCV* EFV DCV* Ledipasvir (NS5A) No data P gp substrate, weak ᴓ P gp, BCRP, OATP1B1 Slide 50 of 54 ARVs allowed in ERADICATE study included EFV, RPV, RAL, need data with HIV PIs ABT450/r (PI) No data No data Ombitasvir No data No data No data (ABT267) (NS5A) Dasabuvir (ABT333) (NNI) No data No data No data ᴓ = inhibitor * managed with DAA dose adjustment Patient s Clinical Course 1 st Month Patient treated with PEG/RBV/SOF Within ~9 days of starting treatment platelets dropped to 88 (nadir 83), ANC dropped to 1.3 (nadir 0.8) Hgb dropped to 12.6 g/dl within 3 weeks (baseline 16.8 g/dl), nadir 11 g/dl symptomatic, RBV reduced to 600QD EPO and GCSF added at 1 month HCV RNA at 1 month IU/mL, but patient changed insurance and missed 5 days of sofosbuvir Slide 51 of 54 17
18 Patient s Clinical Course 2 nd Month Slide 52 of 54 Hgb improving, increased RBV to 800mg QD then 1000mg QD Platelets 93, ANC 0.7 By 6 weeks, HCV RNA < 18 IU/mL (TND) RBV Dose Reduction Does Not Compromise SVR with PEG/RBV/SOF Slide 53 of 54 *Hgb<10g/dL Pooled data from NEUTRINO, FISSION, FUSION, VALENCE. Sulkowski MS, HepDART 2013 Conclusions Slide 54 of 54 Efficacy rates appear similar in HIV and HCV coinfected patients Only difference in treating HIV and HCV patients is drug interaction potential with ARV Currently DDI are not a major concern in HCV treatment but don t get too comfortable in near future, DDI identification and management will likely be important 18
Can we afford to Cure all HIV-HCV Co-infected Patients of HCV?
Can we afford to Cure all HIV-HCV Co-infected Patients of HCV? Michael S. Saag, MD Professor of Medicine University of Alabama at Birmingham Birmingham, Alabama FINAL AU EDITED: 09-17-14 Disclosure Dr
More informationTough Cases in HIV/HCV Coinfection
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Tough Cases in HIV/HCV Coinfection John Scott, MD, MSc Assistant Professor University of Washington Presentation prepared by: J Scott Last Updated: Jun 5, 2014
More informationHIV/HCV Co-Infection
HIV/HCV Co-Infection 2015 Kentucky Conference on Viral Hepatitis Matt Cave, M.D. Associate Professor Department of Medicine Division of Gastroenterology, Hepatology, & Nutrition Department of Pharmacology
More informationPotential Issues in Treating HIV/HCV co-infection with new HCV antivirals
State of the Art in Hepatitis C Virus Infection in HIV/HCV-Coinfected Patients FORMATTED: 11/17/15 David L. Wyles, MD Associate Professor of Medicine University of California San Diego San Diego, California
More information6/2/2015. Interactive Case-Based Presentations and Audience Discussion
Interactive Case-Based Presentations and Audience Discussion Arthur Y. Kim, MD Assistant Professor of Medicine Harvard Medical School Director, Viral Hepatitis Clinic Massachusetts General Hospital Boston,
More informationCase 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA
Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on
More informationTreatments of Genotype 2, 3,and 4: Now and in the future
Treatments of Genotype 2, 3,and 4: Now and in the future THERAPY FOR THE TREATMENT OF GENOTYPE 2 1 GT 2 and GT 3 Treatment-Naïve: SOF+RBV vs PEG-IFN+RBV FISSION Study Design HCV GT 2 and GT 3 Treatment-naïve
More informationSlide Presentation. Management of HCV Coinfection Susanna Naggie, MD, MHS
Slide Presentation Management of HCV Coinfection Assistant Professor of Medicine Duke University School of Medicine & Durham VA Medical Center Director of Infectious Diseases Duke Clinical Research Institute
More informationUpdate in the Management of Hepatitis C: What Does the Future Hold
Update in the Management of Hepatitis C: What Does the Future Hold Paul Y Kwo, MD, FACG Professor of Medicine Mdi Medical ldirector, Liver Transplantation tti Gastroenterology/Hepatology Division Indiana
More informationLatest Treatment Updates for GT 2 and GT 3 Patients
Latest Treatment Updates for GT 2 and GT 3 Patients Eric Lawitz, MD, AGAF, CPI Vice President, Scientific and Research Development The Texas Liver Institute Clinical Professor of Medicine University of
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationInitial Treatment of HCV G Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona
Initial Treatment of HCV G1 2016 Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona Disclosure Information Disclosure Information Dr. Vargas receives
More informationDr Janice Main Imperial College Healthcare NHS Trust, London
BHIVA AUTUMN CONFERENCE 2014 Including CHIA Parallel Sessions Dr Janice Main Imperial College Healthcare NHS Trust, London 9-10 October 2014, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE
More informationRome, February nd Riunione Annuale AISF th AISF ANNUAL MEETING
Rome, February 20-21 nd 2014 Riunione Annuale AISF 2014 14 th AISF ANNUAL MEETING Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations IFN
More informationLedipasvir-Sofosbuvir (Harvoni)
HEPATITIS WEB STUDY HEPATITIS C ONLINE Ledipasvir-Sofosbuvir (Harvoni) Robert G. Gish MD Professor, Consultant, Stanford University Medical Center Senior Medical Director, St Josephs Hospital and Medical
More information4/30/2015. Interactive Case-Based Presentations and Audience Discussion. Debika Bhattacharya, MD, MSc. Learning Objectives
4/3/215 Interactive Case-Based Presentations and Audience Discussion Debika Bhattacharya, MD, MSc Assistant Clinical Professor University of California Los Angeles Los Angeles, California Formatted:4-27-215
More informationHepatitis C Emerging Treatment Paradigms
Hepatitis C Emerging Treatment Paradigms David R Nelson MD Assistant Vice President for Research Professor of Medicine Director, Clinical and Translational Science Institute University of Florida Gainesville,
More informationWhy make this statement?
HCV Council 2014 10 clinical practice statements were evaluated by the Council A review of the available literature was conducted The level of support and level of evidence for the statements were discussed
More information8/5/2014. A new era of HCV clinical management. Direct-Acting Antivirals for Hepatitis C. Goal of HCV treatment is viral cure HIV HBV HCV
NS5B NS5B 8/5/214 A new era of HCV clinical management Mark Sulkowski, MD Professor of Medicine Medical Director, Viral Hepatitis Center Divisions of Infectious Disease and Gastroenterology/Hepatology
More information3/28/2016. The Top 5 Things to Remember about Treating HCV
The Top 5 Things to Remember about Treating HCV Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University School of Medicine Durham, North Carolina FORMATTED: MM/DD/YY New York, New York:
More informationHepatitis C Treatment 2014
Hepatitis C Treatment 214 Brendan M. McGuire, MD UAB Liver Center Outline Epidemiology/National History Terminology for Treatment Treatment Considerations Current Treatment Options Genotype 1 (GT 1) Genotype
More informationTreatment of HCV in HIV/HCV Coinfection
Treatment of HCV in HIV/HCV Coinfection Michael S. Saag, MD Associate Dean, Global Health Professor of Medicine Director, Center for AIDS Research University of Alabama at Birmingham Birmingham, Alabama
More information6/2/2015. Interactive Case-Based Presentations and Audience Discussion
6/2/215 Interactive Case-Based Presentations and Audience Discussion Andrew Aronsohn, MD Assistant Professor of Medicine University of Chicago Medical Center Chicago, Illinois Formatted:5-6-215 Washington,
More informationCase #1. Pharmacology and Drug Interactions of Newer Direct-Acting Antivirals
Pharmacology and Drug Interactions of Newer Direct-Acting Antivirals Charles W. Flexner, MD Professor of Medicine, Pharmacology, and International Health The Johns Hopkins University School of Medicine
More informationThe HCV Pipeline Ira M. Jacobson, MD, FACP, FACG, AGAF. Slide Presentation. IFN-free DAA combinations (G1)
Slide Presentation The HCV Pipeline Vincent Astor Distinguished Professor of Medicine Chief, Division of Gastroenterology and Hepatology Medical Director, Center for the Study of Hepatitis C Weill Cornell
More informationFeeling right at home
Feeling right at home Getting to Cure From Cure to Eradication Jordan J. Feld MD MPH Toronto Centre for Liver Disease Sandra Rotman Centre for Global Health University of Toronto SVR Dramatic Improvements
More informationProgram Disclosure. Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.5 contact hours.
Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint-sponsorship
More informationAssociate Professor of Medicine University of Chicago
Nancy Reau, MD Associate Professor of Medicine University of Chicago Management of Hepatitis C: New Drugs and New Paradigms HCV is More Lethal than HIV Infection HCV superseded HIV as a cause of death
More informationCurrent State of Treatment for HCV. Nancy Reau, MD Associate Professor of Medicine University of Chicago
Activity Code FA376 Current State of Treatment for HCV Nancy Reau, MD Associate Professor of Medicine University of Chicago Learning Objectives Upon completion of this presentation, learners should be
More informationFuture strategies with new DAAs
Future strategies with new DAAs Ola Weiland professor New direct antiviral drugs Case no 1 male with genotype 2b Male with gt 2b chronic HCV Male with gt 2b relapse afer peg-ifn + RBV during 24 weeks
More informationSHOULD EVERYONE WITH HCV/HIV COINFECTION BE TREATED NOW?
SHOULD EVERYONE WITH HCV/HIV COINFECTION BE TREATED NOW? Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Disclosures
More informationHCV In 2015: Maximizing SVR
HCV In 2015: Maximizing SVR Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia ramji_a@hotmail.com Disclosures (within Last
More informationAddressing Unmet Medical Needs in HCV Genotype 3
Addressing Unmet Medical Needs in HCV Genotype 3 Karen Doucette, MD, MSc (Epi), FRCPC Associate Professor, Division of Infectious Diseases, Department of Medicine University of Alberta Objectives Identify
More informationUpdate on the Treatment of HCV
Update on the Treatment of HCV K. Rajender Reddy, MD Professor of Medicine Director of Hepatology Director, Viral Hepatitis Center University of Pennsylvania Philadelphia, USA 1 K. Rajender Reddy, MD Disclosure
More informationHIV Infection with HCV Future Directions
HIV Infection with HCV Future Directions Dr Ranjababu (Babu) Kulasegaram Consultant Physician in HIV/GU Medicine Guy s and St Thomas NHS Foundation Trust London, UK Presenter disclosure information Dr
More informationPivotal New England Journal of Medicine papers 2014 Phase 3 Trial data
4 th HCV Therapy Advances Meeting Paris, December 12-13, 14 Pivotal New England Journal of Medicine papers 14 Phase 3 Trial data Stefan Zeuzem, MD University of Frankfurt Germany Disclosures Consultancies:
More informationWill difficult-to-treat patients remain difficultto-treat. generation of treatments?
Will difficult-to-treat patients remain difficultto-treat with the new generation of treatments? Jordan J Feld MD MPH Toronto Centre for Liver Disease Sandra Rotman Centre for Global Health University
More informationTreatement Experienced patients without cirrhosis. Rafael Esteban Hospital Universitario Valle Hebron Barcelona
Treatement Experienced patients without cirrhosis Rafael Esteban Hospital Universitario Valle Hebron Barcelona Agenda With IFN PegIFN+ Ribavirin + Simeprevir PegIFN+ Ribavirin+ Sofosbuvir Without IFN Sofosbuvir
More informationICVH 2016 Oral Presentation: 28
Ledipasvir/Sofosbuvir Is Safe and Effective for the Treatment of Patients with Genotype 1 Chronic HCV Infection in Both HCV Mono- and HIV/HCV Coinfected Patients A Luetkemeyer 1, C Cooper 2, P Kwo 3, K
More information47 th Annual Meeting AISF
47 th Annual Meeting AISF Rome, 21 February 2014 Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations (HCV/HIV coinfection, advanced cirrhosis,
More informationProfessor David Back
THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Professor David Back University of Liverpool 1-4 April 2014, Arena and Convention Centre Liverpool THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Professor
More informationTreatment of chronic hepatitis C in HIV co-infected patients
Treatment of chronic hepatitis C in HIV co-infected patients Vicente Soriano Department of Infectious Diseases Hospital Carlos III, Madrid, Spain The most prevalent chronic viral infections in humans HBV
More informationHow to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France
How to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France Paris Hepatitis Conference, January 12, 2016 Disclosures I have received funding
More informationDuncan Webster, BSc, BA, MA, MD, FRCPC
Moderator Duncan Webster, BSc, BA, MA, MD, FRCPC Internist, Infectious Disease Physician, Department of Medicine Medical Microbiologist, Department of Laboratory Medicine, Saint John Regional Hospital
More informationHIV-HCV Co-Infection. George Mason University Falls Church, Virginia. Overview. Prevalence of HCV co-infection Incidence and Recent Trends
HIV-HCV Co-Infection Zobair Younossi MD, MPH, FACG, AGAF, FAASLD Chairman, Department of Medicine, Inova Fairfax Hospital Vice President for Research, Inova Health System Professor of Medicine, VCU-Inova
More informationHepatitis C Virus: HIV/Hepatitis C Coinfection Wednesday, August 24, 2016
Hepatitis C Virus: HIV/Hepatitis C Coinfection Debika Bhattacharya, MD, MSc Associate Clinical Professor University of California Los Angeles Los Angeles, California Washington, DC: August 24, 2016 Slide
More informationHIV and Hepatitis C: Advances in Treatment
NORTHWEST AIDS EDUCATION AND TRAINING CENTER HIV and Hepatitis C: Advances in Treatment John Scott, MD, MSc Asst Professor University of Washington Presentation prepared & presented by: John Scott, MD,
More informationPharmacologic Considerations when using DAAs in Cirrhosis
Pharmacologic Considerations when using DAAs in Cirrhosis Jennifer J. Kiser, PharmD Assistant Professor University of Colorado Denver 1 st International Workshop on the Optimal Use of DAAs in Liver Transplant
More informationDirect Acting Antivirals for the Treatment of Hepatitis C Infection
Hepatitis C Core Curriculum, Module 2 Direct Acting Antivirals for the Treatment of Hepatitis C Infection Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP Objectives Discuss the evolution of hepatitis C treatment
More information10/21/2016. Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina. Learning Objectives
A Crash Course on the AASLD/IDSA Hepatitis C Virus Infection Treatment Guidelines: What s New Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina FORMATTED: 1/3/16
More informationHIV/HCV Coinfection: Why It Matters and What To Do About It. Cody A. Chastain, MD 10/26/16
HIV/HCV Coinfection: Why It Matters and What To Do About It Cody A. Chastain, MD 10/26/16 Disclosures I have no relevant financial disclosures. Objectives At the end of this lecture, the learner will be
More information10/4/2016. Management of Hepatitis C Virus Genotype 2 or 3 Infection
Management of Hepatitis C Virus Genotype 2 or 3 Infection Kenneth E. Sherman, MD, PHD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati Cincinnati, Ohio FORMATTED:
More informationHCV Treatment of Genotype 1: Now and in the Future
HCV Treatment of Genotype 1: Now and in the Future Bruce R. Bacon, MD, FACG James F. King, MD Endowed Chair in Gastroenterology Professor of Internal Medicine Co-Director of the Abdominal Transplant Program
More informationA treatment revolution: current management for chronic HCV
A treatment revolution: current management for chronic HCV Ray Chung, M.D. Director of Hepatology and Liver Center Kevin and Polly Maroni Research Scholar Massachusetts General Hospital Disclosures Research
More informationMeet the Professor: HIV/HCV Coinfection
Meet the Professor: HIV/HCV Coinfection Vincent Lo Re, MD, MSCE Assistant Professor of Medicine and Epidemiology Division of Infectious Diseases Center for Clinical Epidemiology and Biostatistics University
More informationScope of the problem 6/2/2015
Interactive Case-Based Presentations and Audience Discussion Arthur Y. Kim, MD Assistant Professor of Medicine Harvard Medical School Director, Viral Hepatitis Clinic Massachusetts General Hospital Boston,
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS This information is intended for payers only. The HCV-TARGET and TRIO studies were supported by Gilead Sciences, Inc. Real-world experience data
More informationEmerging Therapies for HCV: Highlights from AASLD 2012 (Part 2)
Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2) PegIFN and RBV remain vital components of HCV therapy-- selected presentations from: Program Disclosure This activity has been planned and
More informationEvolution of Therapy in HCV
Hepatitis C: Update on New Therapies and AASLD 13 David Bernstein, MD, FACP, AGAF, FACP Professor of Medicine Hofstra North Shore-LIJ School of Medicine Evolution of Therapy in HCV 199 1999 1 13 (%) SVR
More informationClinical Management: Treatment of HCV Mono-infection
Clinical Management: Treatment of HCV Mono-infection Curtis Cooper, MD, FRCPC Associate Professor-University of Ottawa The Ottawa Hospital- Infections Diseases Viral Hepatitis Program- Director Industry
More informationManagement of HIV/HCV Coinfection. Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, NY
Management of HIV/HCV Coinfection Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, NY Disclosure Dr. Marks has received grants and research support from Gilead Sciences
More informationHepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors
Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Fred Poordad, MD The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science Center
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS MAY 217 This information is intended for payers only. The HCV-TARGET study was supported by Gilead Sciences, Inc. Real-world experience data were
More informationApproved regimens for cirrhotic patients
5th Workshop on HCV THERAPY ADVANCES New antivirals in clinical practice Approved regimens for cirrhotic patients Amsterdam, 4-5 december 2015 Disease burden in Spain 400000 350000 300000 F0 Peak cirrhosis
More informationHCV Treatment: Why to Wait
HCV Treatment: Why to Wait Prof. Jean-Michel Pawlotsky, MD, PhD National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital University of Paris-Est
More informationEmerging Therapies for HCV: Highlights from AASLD 2012 (Part 2)
Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2) Goals for Hepatitis C Therapy Compared to PegIFN α/rbv, new treatment regimens for chronic hepatitis C should offer: Improved efficacy Efficacy
More informationHCV-G3: Sofosbuvir with ledipasvir or daclatasvir?
HCV-G3: Sofosbuvir with ledipasvir or daclatasvir? Ioannis Goulis, MD Aristotelian University of Thessaloniki XXIII International Hepatitis B & C Meeting of Athens Hadziyannis HCV genotype 3 therapy Chronic
More informationHepatitis C in Special Populations
Hepatitis C in Special Populations David E. Bernstein, MD, FACG Vice Chairman of Medicine for Clinical Trials Chief, Division of Hepatology and Sandra Atlas Bass Center for Liver Diseases Northwell Health
More informationWhat is the Optimized Treatment Duration? To Overtreat versus Undertreat. Nancy Reau, MD Associate Professor of Medicine University of Chicago
What is the Optimized Treatment Duration? To Overtreat versus Undertreat Nancy Reau, MD Associate Professor of Medicine University of Chicago Learning Objectives: 1. Discuss patient populations appropriate
More informationClinical Pharmacology of DAA s for HCV: What s New and What s in the Pipeline
Clinical Pharmacology of DAA s for HCV: What s New and What s in the Pipeline Anita Mathias, PhD Clinical Pharmacology, Gilead Sciences 14 th Int. Workshop on Clinical Pharmacology of HIV Therapy April
More informationEASL 2013 Interferon Free, All Oral Regimens for Hepatitis C. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C Maria Buti Hospital Universitario Valle Hebron Barcelona Spain The first Results with Oral therapy: a Protease Inhibitor and NS5A inhibitor
More informationCase 2: A 71-year-old man with cirrhosis
Case 2: A 71-year-old man with cirrhosis 1 JM, 71 year old African American male with known cirrhosis Asymptomatic apart from fatigue No prior history of decompensation Past history: Diabetes for 11 years
More informationCase #1. Case #1. Case #1: Audience vote VS. The Great Debate: When to Treat HCV in our HIV coinfected patients
Case #1 The Great Debate: When to Treat HCV in our HIV coinfected patients Medical Management of AIDS December, 2012 Moderated by George Beatty,MD 35 year old African American man, CD4 + 450, HIV RNA
More informationHCV Case Study. Treat Now or Wait for New Therapies
HCV Case Study Treat Now or Wait for New Therapies This program is supported by educational grants from Kadmon and Merck Pharmaceuticals. Program Disclosure This activity has been planned and implemented
More information6/2/2015. Interactive Case-Based Presentations and Audience Discussion
Interactive Case-Based Presentations and Audience Discussion Charles W. Flexner, MD Professor of Medicine, Pharmacology, and International Health The Johns Hopkins University Baltimore, Maryland Formatted:05-05-2015
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C First Generation Agents Page 1 of 16 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C First Generation Agents - Through Preferred
More informationHEPATITIS WEB STUDY. Treatment of Hepatitis C following Liver Transplantation
HEPATITIS WEB STUDY Treatment of Hepatitis C following Liver Transplantation Terry D. Box, MD Associate Professor of Medicine Division of Gastroenterology/Hepatology University of Utah Health Sciences
More informationNew developments in HCV research and their implications for front-line practice
New developments in HCV research and their implications for front-line practice Dr. Curtis Cooper Associate Professor, University of Ottawa Director, Ottawa Hospital Viral Hepatitis Program June 17, 2013
More informationUpdated Guidelines for Managing HIV/HCV Co-Infection
Updated Guidelines for Managing HIV/HCV Co-Infection John J Faragon, PharmD, BCPS, AAHIV-P Regional Pharmacy Director, NY/NJ AIDS Education and Training Center Pharmacist, HIV Medicine, Albany Medical
More informationTopic: Sovaldi, sofosbuvir Date of Origin: March 14, Committee Approval Date: August 15, 2014 Next Review Date: March 2015
Medication Policy Manual Policy No: dru332 Topic: Sovaldi, sofosbuvir Date of Origin: March 14, 2014 Committee Approval Date: August 15, 2014 Next Review Date: March 2015 Effective Date: October 1, 2014
More informationHepatitis C: New Antivirals in the Liver Transplant Setting. Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona
Hepatitis C: New Antivirals in the Liver Transplant Setting Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona Patient survival Hepatitis C and Liver Transplantation Years after transplantation
More informationVII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES
VII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES REGIMENES TERAPÊUTICOS DE LA HEPATITIS C, INTERFERÓN FREE A Coruña 2 Febrero 2013 Rui Sarmento e Castro Centro Hospitalar do Porto HJU ECS Universidade
More information8/11/2014 HIV/HCV CO-INFECTION: RECENT ADVANCES AND NEW OPPORTUNITIES HISTORY NEVER LOOKS LIKE HISTORY WHEN YOU ARE LIVING THROUGH IT.
HIV/HCV CO-INFECTION: RECENT ADVANCES AND NEW OPPORTUNITIES Jacob Langness, PharmD, BCPS Clinical Pharmacy Specialist HIV and Hepatology HISTORY NEVER LOOKS LIKE HISTORY WHEN YOU ARE LIVING THROUGH IT
More informationSVR Updates from the 2013 EASL
Updates from the 2013 EASL By Tracy Swan, Treatment Action Group Streamlining HCV Treatment Treatment for hepatitis C virus (HCV) is becoming simpler, shorter, and more effective. All-oral combinations
More informationTREATMENT OF GENOTYPE 2
Treatment of Genotype 2, 3,and 4 David E. Bernstein, MD, FACG Advisory Committee/Board Member: AbbVie Pharmaceuticals, Gilead, Merck, Janssen Consultant: AbbVie Pharmaceuticals, Bristol-Myers Squibb, Gilead,
More informationHIV-HCV coinfection. Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Baltimore, Maryland
HIV-HCV coinfection Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Baltimore, Maryland Disclosures Principal investigator for research grants Funds paid to Johns Hopkins
More informationAntiviral treatment in Unique Populations
Antiviral treatment in Unique Populations Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Unique HCV Populations HIV/HCV co-infected
More informationOmbitasvir-Paritaprevir-Ritonavir + Dasabuvir (Viekira Pak)
HEPATITIS WEB STUDY HEPATITIS C ONLINE Ombitasvir-Paritaprevir-Ritonavir + Dasabuvir (Viekira Pak) Prepared by: Sophie Woolston, MD and David H. Spach, MD Last Updated: December 29, 2014 OMBITASVIR-PARITAPREVIR-RITONAVIR
More informationTreatment of Hepatitis C in HIV-Coinfected Patients. Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain
Treatment of Hepatitis C in HIV-Coinfected Patients Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain Estimated no. of persons infected with HIV and hepatitis viruses
More informationTreating now vs. post transplant
Resistance with treatment failure Treating now vs. post transplant Pros (for treating pre transplant) If SVR efficacy means Better quality of life Removal from waiting list No post transplant recurrence
More informationSaeed Hamid, MD Alex Thompson, MD, PhD
Saeed Hamid, MD Alex Thompson, MD, PhD 1 We will review some top line data from EASL Majority of the time discussing how the data affects daily practice 2 Grazoprevir (GZR; MK-5172) + Elbasvir (EBR; MK-
More informationTreatment of HCV infection in daily clinical practice. Which are the optimal options for Genotypes 2 and 3? Jiannis Vlachogiannakos
Treatment of HCV infection in daily clinical practice. Which are the optimal options for Genotypes 2 and 3? Jiannis Vlachogiannakos Associate Professor of Gastroenterology Academic Department of Gastroenterology
More informationPhase 3. Treatment Experienced. Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2. Afdhal N, et al. N Engl J Med. 2014;370:
Phase 3 Treatment Experienced Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Afdhal N, et al. N Engl J Med. 2014;370:1483-93. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Experienced HCV
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C First Generation Agents Page 1 of 18 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C First Generation Agents - Through Preferred
More informationSeparate clinical trials for HIV- HCV coinfected patients are NOT a necessity. Patrick Ingiliz, Berlin
Separate clinical trials for HIV- HCV coinfected patients are NOT a necessity Patrick Ingiliz, Berlin Back in the days when HCV genotype 1 was the problem SVR (%) 100 90 80 70 60 50 40 30 20 10 0 35% PRESCO
More informationIntroduction. The ELECTRON Trial
63rd AASLD November 9-13, 12 Boston, Massachusetts Faculty Douglas T. Dieterich, MD Professor of Medicine and Director of CME Department of Medicine Director of Outpatient Hepatology Division of Liver
More informationDr. Siddharth Srivastava
Dr. Siddharth Srivastava MD, DM (Gastroenterology) Associate Professor GIPMER, New Delhi Rashtriya Gaurav Award 2013 for work on hepatitis B and C Set up Liver clinic at GIPMER and in charge EUS laboratory.
More informationExperience with pre-transplant antiviral treatment: PEG/RBV and DAA. Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona
Experience with pre-transplant antiviral treatment: PEG/RBV and DAA Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona Interferon-free regimens G1b nulls Asunaprevir (PI) + Daclatasvir
More informationDisclosures. Advanced HCV management. Overview. Renal failure 1/10/2018. Research Grant support to UCSF from AbbVie Gilead Merck Proteus NIH
Disclosures Advanced HCV management Annie Luetkemeyer, MD Division of HIV, ID and Global Medicine ZSFG, UCSF Research Grant support to UCSF from AbbVie Gilead Merck Proteus NIH Overview Renal failure Acute
More informationSURVEYOR-II Part 2 Study Design
HIGH SVR RATES WITH + CO-ADMINISTERED FOR 8 WEEKS IN NON-CIRRHOTIC PATIENTS WITH HCV GENOTYPE 3 INFECTION A.J. Muir, S. Strasser, S. Wang, S. Shafran, M. Bonacini, P. Kwo, D. Wyles, E. Gane, S.S. Lovell,
More information